Ion channels encoded by KCNQ2-5 generate a prominent K+ conductance in the central nervous system, referred to as the M current, which is controlled by membrane voltage and PIP2. The KCNQ2-5 voltage-gated potassium channels are targeted by a variety of activating compounds that cause negative shifts in the voltage dependence of activation. The underlying pharmacology of these effects is of growing interest because of possible clinical applications. Recent studies have revealed multiple binding sites and mechanisms of action of KCNQ activators. For example, retigabine targets the pore domain, but several compounds have been shown to influence the voltage-sensing domain. An important unexplored feature of these compounds is the influence of channel gating on drug binding or effects. In the present study, we compare the state-dependent actions of retigabine and ICA-069673 (ICA73, a voltage sensor–targeted activator). We assess drug binding to preopen states by applying drugs to homomeric KCNQ2 channels at different holding voltages, demonstrating little or no association of ICA73 with resting states. Using rapid solution switching, we also demonstrate that the rate of onset of ICA73 correlates with the voltage dependence of channel activation. Retigabine actions differ significantly, with prominent drug effects seen at very negative holding voltages and distinct voltage dependences of drug binding versus channel activation. Using similar approaches, we investigate the mechanistic basis for attenuation of ICA73 actions by the voltage-sensing domain mutation KCNQ2[A181P]. Our findings demonstrate different state-dependent actions of pore- versus voltage sensor–targeted KCNQ channel activators, which highlight that subtypes of this drug class operate with distinct mechanisms.
Voltage-gated potassium channels in the KCNQ (Kv7) family encode the M current, a prominent neuronal potassium current with dual regulation by voltage and PIP2 (Suh et al., 2006; Suh and Hille, 2007). The M current was first named because of its identification as a potassium current that was inhibited by extracellular ligands of muscarinic acetylcholine receptors, although these currents are now recognized as important regulators of neuronal excitability in response to a variety of extracellular signals (Adams and Brown, 1980; Brown and Adams, 1980; Brown et al., 2007; Hernandez et al., 2008). The KCNQ channels also have unique pharmacological properties, highlighted by their susceptibility to activation by an emerging class of voltage-gated potassium channel openers (Barrese et al., 2018; Miceli et al., 2018). The prototype drug in this class, retigabine, causes a hyperpolarizing shift of the voltage dependence of activation of channels that contain KCNQ2-5 subtypes, and this effect depends on the presence of a conserved Trp residue (Trp 236 in KCNQ2) in retigabine sensitive KCNQ channels (Schenzer et al., 2005; Wuttke et al., 2005; Lange et al., 2009; Kim et al., 2015).
The primary clinical application of KCNQ channel activators has been the treatment of pharmacoresistant epilepsy, and this is partly related to the recognition that KCNQ2 and KCNQ3 are associated with inheritable forms of epilepsy, varying in severity from benign familial neonatal seizures to epileptic encephalopathy (Biervert et al., 1998; Charlier et al., 1998; Singh et al., 1998; Martyn-St James et al., 2012). Mutations in KCNQ4 channels have also been linked to age-related deafness (Kubisch et al., 1999; Kharkovets et al., 2006). In addition to utility in epilepsy, applications for treatment of tinnitus, hypertension, pain, and neurodegenerative diseases are also being explored (Mackie and Byron, 2008; Xu et al., 2010; Wainger et al., 2014; Kalappa et al., 2015; Kumar et al., 2016; Vicente-Baz et al., 2016). Production of retigabine was recently discontinued because of low usage and some undesirable side effects including urinary retention and localized blue pigmentation in some patients. However, the identification of Kv7 channels as targets for diseases of hyperexcitability has led to the development of a variety of openers (Miceli et al., 2008, 2018; Xiong et al., 2008) including phenamates (diclofenac and meclofenamic acid derivatives; Peretz et al., 2010), zinc pyrithione, (Xiong et al., 2007), BMS-204352, and the acrylamide compound (S)-1 (Bentzen et al., 2006). Last, a class of substituted benzamides including ICA-069673, ICA-27234, ICA-110381, ztz-240, and ML-213 exhibit activity as Kv7 openers (Wickenden et al., 2008; Gao et al., 2010; Yu et al., 2011). Of these, the most well documented in preclinical anticonvulsant models is ICA-27243, although our group has primarily used ICA-069673 (ICA73) to investigate the mechanism of action on KCNQ channels (Padilla et al., 2009; Wang et al., 2017).
Recognition of diverse mechanisms of action of KCNQ openers originated with the demonstration that ICA-27243 retained activity on mutant channels lacking the conserved pore Trp residue known to be essential for retigabine activity (Xiong et al., 2008; Padilla et al., 2009; Gao et al., 2010; Peretz et al., 2010). Moreover, ICA-27243 exhibited greater subtype specificity, enhancing Q2/3 current but not Q3/5 or Q3 homomeric current (Wickenden et al., 2008; Blom et al., 2010). A series of chimeric channels between drug-sensitive and insensitive subunits revealed that residues in the KCNQ2 voltage-sensing domain (VSD) were important for ICA73 and ICA-27243 effects, and our group recently identified two residues in the S3 helix of the KCNQ2 VSD that are critical for ICA sensitivity: A181 and F168 (Padilla et al., 2009; Wang et al., 2017). Mutations at either of these positions weaken or abolish ICA73-mediated gating effects but retain retigabine sensitivity. This provides further support that ICA73 and retigabine have distinct binding sites and may act through different mechanisms.
Use-dependent interactions are often considered to be a useful property of small-molecule ion channel modulators. The most widely studied example is use-dependent actions of many voltage-dependent sodium channel blockers, which preferentially stabilize the inactivated channel state and thereby exert stronger effects in hyperexcitable cells (Ragsdale et al., 1994). Although the anticonvulsant properties of KCNQ openers are well known, their use-dependent properties and fundamental mechanisms of action have not been described in detail. In this study, we characterized the state dependence of interaction of retigabine and ICA73 with homomeric KCNQ2 channels. Our findings demonstrate that in addition to acting via different binding sites, these compounds also have fundamentally different mechanisms of action. The ICA73 appears to bind almost exclusively to activated channel states. In contrast, retigabine exhibits less prominent state-dependent accessibility. Collectively with the differences in mutations that alter sensitivity to these drugs, our findings demonstrate the presence of at least two distinct mechanisms of action of KCNQ channel openers. We also characterize the effects of a voltage sensor mutation that alters sensitivity to ICA73.
Materials and methods
Patch pipettes were manufactured from soda lime capillary glass (Fisher), using a Sutter P-97 puller (Sutter Instrument). When filled with standard recording solutions, pipettes had a tip resistance of 1–3 MΩ. Recordings were filtered at 5 kHz; sampled at 10 kHz, with manual capacitance compensation and series resistance compensation between 70 and 90%; and stored directly on a computer hard drive using an Axopatch 200B amplifier, Digidata 1440 digitizer, and Clampex 10.7 software (Molecular Devices). Series access resistances did not exceed 5 MΩ (usually <3 MΩ). The KCNQ2 channels do not generate large currents in our experimental system (rarely >3 nA at 0 mV). The largest calculated voltage error (see +40 mV trace in Fig. 2 A) was ∼4 mV after 80% series resistance compensation (6 nA * 3 MΩ * [1–0.8]) = 3.6 mV. Bath solution had the following composition: 135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM HEPES and was adjusted to pH 7.4 with NaOH. Pipette solution had the following composition: 135 mM KCl, 5 mM K-EGTA, and 10 mM HEPES and was adjusted to pH 7.2 using KOH. The pipette and bath solutions generate a calculated liquid junction potential of ∼4.3 mV that was not corrected for in the reported experiments. Chemicals were purchased from Sigma-Aldrich or Fisher. Solutions were delivered at room temperature (19–21°C) by pressure-driven flow, through a multibarreled solution delivery turret, driven by the RSC-200 (Biological) rapid solution exchanger to enable solution jumps.
Retigabine was obtained from Toronto Research Chemicals, and ICA73 was obtained from Tocris. Drugs were dissolved in DMSO to yield stock concentrations of 100 mM. Stock solutions were diluted in extracellular solutions to appropriate concentrations for experiments the same day.
Ion channel constructs and expression in cell lines
Human KCNQ2 DNA originally expressed in pTLN vectors, obtained from Dr. M. Taglialatela (University of Naples, Italy) and Dr. T. Jentsch (Max-Delbrück-Centrum für Molekulare Medizin, Germany), were subcloned into pcDNA3.1 (-). The point mutant KCNQ2[A181P] was generated using a two-step overlapping PCR method, then subcloned into pcDNA3.1 using NheI and EcoRI restriction enzymes. Sequences were verified by Sanger sequencing approaches (Genewiz).
The HEK293 cells were maintained in Dulbecco's modified eagle medium supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were grown in Falcon tissue culture–treated flasks, in an incubator at 5% CO2 and 37°C. Cells were plated onto 12-well plates and allowed to settle for 24–48 h before transfection. Cells were transiently transfected with 1 µg of DNA encoding the channel of interest and 500 ng of GFP, using jetPRIME DNA transfection reagent (Polyplus). 24 h after transfection, cells were plated onto sterile coverslips for electrophysiology experiments the following day. Transfected cells were selected/excluded from recordings based on GFP fluorescence and current magnitude. No cells used for data analysis had currents <500 pA at −20 mV. There is also an endogenous K+ current present in the HEK cells used for our recordings. However, the endogenous current is clearly distinguishable from KCNQ2 currents because it has notably faster activation kinetics and does not activate until depolarized voltages near +20 mV. An example of some minor contamination can be as a small (∼200-pA) rapid activation component (see Fig. 4 D).
Conductance–voltage relationships were normalized to the peak conductance in control conditions and fit with a Boltzmann equation:
where A is the ratio of the peak conductance (normalized to peak conductance in control conditions), I/Imax is the normalized tail current magnitude, V is the voltage applied, V1/2 is the half activation voltage, and k is a slope factor reflecting the steepness of the curve. Conductance–voltage relationships from individual cells were fit using a least-squares minimization approach in Microsoft Excel (Solver tool), followed by calculation of descriptive statistics for individual fit parameters (mean ± SEM are used throughout the text). Kinetics of current relaxation were fit with a single exponential time course using Clampfit. Occasionally, the sum of two exponentials was required to achieve a good fit because of the presence of a slow activation component. In that case, the dominant time constant was used for calculation of the rate of drug interaction.
The ICA73 binding is occluded in the KCNQ2 closed state
Application of ICA73 to homomeric KCNQ2 channels causes a dramatic hyperpolarizing gating shift, ∼50% current potentiation at voltages where the activation curve is saturated, and deceleration of channel deactivation (Fig. 1 A; Wang et al., 2017). We investigated state-dependent interaction of ICA73 and KCNQ2 by applying 10 µM ICA73 for ∼1 min while holding the membrane potential at various negative voltages (Fig. 1, B and C). We assessed drug interactions with the channel during the wash-in and incubation, based on the development of a standing current. When cells are held at −120 mV, incubation in 10 µM ICA73 fails to generate any apparent standing current (or instantaneous current upon depolarization) until after the first depolarizing pulse following drug application (Fig. 1 B). However, upon the first depolarization in the presence of ICA73, there is development of a potentiated outward current with nearly identical kinetics to the control pulse (Fig. 1 B, inset normalized activation) and a dramatically decelerated tail current (Fig. 1 B, green) that prevents channel closure before a subsequent pulse 4 s later, leading to a large instantaneous current in subsequent pulses (Fig. 1 B, gray). Application of ICA73 at more depolarized holding voltages caused development of a more prominent standing current during the drug incubation period (Fig. 1 C). These findings indicate that ICA73 interactions with KCNQ2 are influenced by the holding potential, and access to the channel becomes very slow at negative voltages.
This occlusion of ICA73 from resting states is also apparent in the development of the ICA73-mediated slow tail currents (Fig. 1 D). In this experiment, cells were depolarized to +20 mV for varying durations in 10 µM ICA73. The short depolarization (200 ms) elicits primarily rapid deactivation kinetics, whereas a slow component of deactivation becomes much more prominent as the duration of the depolarizing pulse is prolonged (exemplar tails for 200 ms vs. 1,700 ms depolarizations are presented in Fig. 1 E).
The ICA73 binding site access tracks voltage-dependent activation
The ICA73 interactions with the channel were investigated with greater time resolution using rapid solution exchange over a range of voltages (Fig. 2). Cells were stepped between −100 and 40 mV for 1 s, followed by rapid application of 100 µM ICA73 (Fig. 2 A). Based on calibrations with K+ concentration jumps, we estimate that the time constant of solution exchange in these experiments is ∼20 ms (Zhang et al., 2015). The rate of ICA73 interaction with KCNQ2 channels was estimated using the rate of current increase upon drug application. These effects are dependent on ICA73, as identical experiments performed with an equivalent of DMSO (used to generate ICA73 stock solutions) exhibit no current potentiation. The DMSO application causes a very minor rapid blockade (Fig. 2 C) and can also be observed as a small negative current deflection immediately upon drug delivery in Fig. 2 A. In the absence of clear channel opening (at very negative voltages), we could also roughly infer the extent of drug binding based on the properties of current activation in a subsequent pulse to −60 mV (Fig. 2 A).
In the absence of ICA73, only a small fraction of KCNQ2 channels are activated at −60 mV. Upon rapid application of 100 µM ICA73, there is a slow but resolvable current increase (Fig. 2 A). At more positive voltages, the rate of ICA73 current enhancement is accelerated, as exemplified in normalized traces (Fig. 2 B). In contrast, at −100 mV or more negative voltages, ICA73 interactions are very slow because the subsequent pulse to −60 mV exhibits little or no instantaneous current (Fig. 2 A). Also, the time course of activation at −60 mV (after a −100-mV prepulse) is similar to activation after rapid drug application at −60 mV (Fig. 2 A). This observation implies that drug application at −100 mV (or more negative voltages) has a minimal effect until the step to −60 mV, at which point channels behave as if they were rapidly exposed to the drug.
We quantified the rate of interaction as a function of membrane voltage at the time of drug application (Fig. 2, B and D) and plotted these data together with the conductance–voltage relationship, highlighting that the rate of ICA73 interaction closely tracks the voltage dependence of channel activation. Sample single-exponential fits are shown as dashed blue lines (Fig. 2 B), and for clarity, we should mention that occasionally there is a slow activation component that requires a sum of two exponentials to fit (red fit in Fig. 2 B). In those cases, the dominant time constant describing the most significant fraction of current activation was used to assess the rate of drug interaction. Also, at negative voltage the rate becomes difficult to assess precisely because they are slow and begin to appear more sigmoidal. At −80 mV (Fig. 2 B), we further constrained the fit based on the observation that maximal activation is achieved in 100 µM ICA73 at −80 mV (Fig. 1 A).
In these experiments, the rate of interaction varies substantially (∼150-fold) with voltage, from 0.00038 ± 0.00007 ms−1 mM−1 at −80 mV to 0.060 ± 0.008 ms−1 mM−1 at 0 mV. At more negative voltages, we could estimate an upper bound for the rate of interaction based on the magnitude of instantaneous current observed in the step to −60 mV. At −100 mV, there is occasionally a small but convincing instantaneous current (Fig. 2 A), but this is no larger than 20% of the instantaneous current generated by the −80 mV pulse (suggesting ∼750-fold slower access of ICA73 relative to the saturating rate at 0 mV). At more negative voltages, rates are so slow that we cannot confidently measure them in this experiment. The implication of this observation is that the degree of channel activation limits the rate of ICA73 access to its binding site. An important related finding is that the conductance–voltage relationship of KCNQ channels has been previously shown to closely overlap with the voltage dependence of voltage sensor movement (Osteen et al., 2012; Kim et al., 2017). Thus, we suggest that voltage sensor movement gates access to a binding site for ICA73.
We explored these observations further by measuring rates of ICA73 interaction with the KCNQ2[R201A] mutant. This mutation is equivalent to the previously reported KCNQ1[R231C] channel and exhibits a gain of function phenotype arising from a hyperpolarizing shift of the voltage dependence of activation (Fig. 3 A; Osteen et al., 2012). Using similar voltage and solution exchange timing as in Fig. 2, we observed that KCNQ2[R201A] channels exhibited current potentiation leading to complete channel activation at very negative voltages (−120 and −140 mV are shown in Fig. 3 B). In the exemplar data, we have highlighted three regions of interest for direct comparison to WT KCNQ2. In region i, 100 µM ICA73 is rapidly applied, leading to current potentiation of KCNQ2[R201A] but no effect on WT KCNQ2. In region ii (step to −60 mV), it is apparent that ICA73 exposure at −120 mV leads to complete activation of KCNQ2[R201A] but has no effect on WT KCNQ2 until the voltage is stepped to −60 mV. Last, in region iii, it is apparent that closure of [R201A] channels is extremely slow in these conditions, likely because of the intrinsic bias of these channels toward the activated state. Across a range of negative voltages, KCNQ2[R201A] exhibits potentiation by ICA73, whereas WT KCNQ2 is not responsive (Fig. 3 C). This finding demonstrates that accessibility of ICA73 depends on channel conformation, and accessibility at more negative voltages is only apparent in mutants with shifted voltage-dependent gating.
Retigabine readily accesses KCNQ2 closed states
As mentioned, previous reports have suggested a distinct binding site for ICA73 (in the voltage sensor) versus retigabine (in the pore; Padilla et al., 2009; Wang et al., 2017). To compare the mechanism of action of retigabine and ICA73, we performed similar wash-in experiments with 30 µM retigabine, revealing significant differences in channel responses at hyperpolarizing voltages. The effects of retigabine on the KCNQ2 conductance–voltage relationship and deactivation kinetics are much less pronounced than ICA73 (Fig. 4 A). However, incubation in 30 µM retigabine caused development of a prominent standing current over a wide voltage range (−120 to −60 mV), and acceleration of channel activation is apparent in the presence of retigabine, as previously reported (Main et al., 2000; Wickenden et al., 2000). In contrast to ICA73 (Fig. 1), these findings indicate that retigabine can more readily access resting states of the channel. It was also clear that both short and long depolarizations in retigabine generated deceleration of tail current kinetics (Fig. 4, D–F). This finding contrasts with the effects of ICA73 using similar experimental protocols (Fig. 1, D and E) and suggests that retigabine interacts readily with channel resting states.
Using rapid solution exchange for time-resolved retigabine application, we confirmed that drug association is rapid even at voltages where channels are predominantly closed (Fig. 5). As noted previously, some traces required a sum of two exponentials (highlighted in green in this cases), and we used the dominant time constant to assess the interaction rate. At −80 mV, although currents are small (close to the reversal potential for potassium), the onset of channel opening after retigabine application can still be resolved and is only modestly slower (0.018 ± 0.001 ms−1 mM−1) than at 0 mV (0.05 ± 0.01 ms−1 mM−1; Fig. 5, B and C). This finding suggests retigabine interaction with KCNQ2 channels is not gated by channel opening and closing. However, there does appear to be a steep voltage-dependent change in the rate of retigabine-mediated current potentiation between −60 and −80 mV (Fig. 5, B and C). Unlike ICA73 (Fig. 3), this reduction in rate does not coincide with the voltage dependence of channel activation. Also, voltage clamp fluorometry and gating current records from other KCNQ channel types (KCNQ1, KCNQ3, and KCNQ4) indicate that voltage sensor movement has similar voltage dependence to channel activation (Miceli et al., 2009; Osteen et al., 2012; Kim et al., 2017). Although we cannot correlate this change in rate with an experimentally observable state transition, another possibility is that retigabine is occluded from a state early in the activation pathway.
We further investigated retigabine interactions with KCNQ2 channels at negative voltages, keeping in mind other observations related to retigabine association with preopen states. Most importantly, channel activation is consistently accelerated in the presence of retigabine (Fig. 4, D and E, and also further characterization in Fig. 6). This differs from ICA73 (Fig. 1 B) and implies that retigabine can bind to resting channel states (or binds to some preopen state in the activation pathway and accelerates subsequent steps). We performed additional rapid perfusion experiments using lower ICA73 and retigabine concentrations to distinguish the apparent drug interaction rate from channel gating. We measured channel behavior when 5 µM retigabine was applied simultaneously with a voltage step to −40 mV and compared this with channel activation observed after brief (1–2 s) retigabine applications at −100 mV (Fig. 6 A). The rate of current increase is slow when retigabine is applied simultaneously with a step to −40 mV, reflecting a combination of channel activation and slow drug association. In contrast, if 5 µM retigabine is applied while channels are held at −100 mV for 1 or 2 s, subsequent steps to −40 mV exhibit much faster activation. This finding suggests that channels have bound the drug while at −100 mV, enabling rapid activation upon depolarization to −40 mV. This behavior contrasts with ICA73 in identical experiments (Fig. 6 B). When 5 µM ICA73 is applied simultaneously with a voltage step to −40 mV, there is a slow rate of current increase. Unlike for retigabine, kinetics of channel activation at −40 mV are not altered if ICA73 is preapplied at −100 mV, consistent with our prior conclusion that ICA73 is strongly excluded when channels are held at −100 mV. Although the effects of these drugs are qualitatively consistent, there is often variation in the appearance of multiple activation components between cells. Therefore, we compared the effects of ICA73 and retigabine by measuring the 50% current rise time (Fig. 6 C), highlighting the retigabine-mediated acceleration of channel activation observed when the drug is administered at −100 mV.
From observations like these, we infer that significant association of retigabine occurs even during brief exposures at negative voltages because channel activation is accelerated in subsequent depolarizing steps. Revisiting the apparent voltage-dependent reduction in the rate of retigabine interaction in Fig. 5 C, we should mention the shortcoming of using currents as a proxy for measuring drug binding. In the case of retigabine, this is a challenge at more negative voltages (e.g., −80 and −100 mV) because a significant fraction of channels remain closed, even in saturating retigabine concentrations (Fig. 4 A). Thus, the rate that is attributed to retigabine association (e.g., Fig. 5 B; −80 mV) is likely strongly influenced by the gating transitions of retigabine-bound channels at these negative voltages (and high retigabine concentrations). Note that the effects of 5 µM retigabine appear complete after ∼2 s at −100 mV (Fig. 6 A), comparable to the rate of current enhancement in 100 µM retigabine despite a 20-fold lower concentration (Fig. 5 B). This observation suggests that retigabine association in saturating conditions occurs faster than we can detect based on current measurements in Fig. 5 B and that the measured rate reflects gating transitions of channels that are already bound to retigabine. This is also consistent with the observation that voltage-dependent changes in retigabine rates (Fig. 5 C) occur in approximately the same voltage range as the fully shifted conductance–voltage relationship of KCNQ2 in saturating retigabine concentrations (V1/2, approximately −80 mV; Fig. 4 A).
Channel closure requires ICA73 unbinding
Findings thus far suggest marked differences in the state accessibility of ICA73 and retigabine. We further investigated the state accessibility of these KCNQ openers by examining channel reopening in the presence of retigabine and ICA73. We had noted that activation kinetics of KCNQ2 in the presence of ICA73 were not altered significantly from control conditions, in contrast to the pronounced acceleration of channel activation observed in the presence of retigabine (Figs. 1, 2, 3, 4, 5, and 6). We reasoned that this is likely a reflection of different closed state binding properties of these drugs. That is, accelerated activation kinetics in the presence of retigabine might indicate binding and destabilization of resting states. In contrast, closed KCNQ2 channels appear to have much lower accessibility for ICA73 and therefore would be predicted to activate with kinetics similar to control (and subsequently bind the drug after they reach an activated state). To test this difference, we delivered a depolarizing stimulus (0 mV) in the presence of each drug, repolarized for varying durations (Δ time in Fig. 7, A and C), to allow varying degrees of channel closure, and then depolarized again. We compared the activation kinetics of channels that closed during the repolarizing interpulse interval with activation kinetics in control conditions (normalized traces in Fig. 7, B and D; multiple repolarization times are highlighted in different shades). In retigabine, the activating fraction consistently exhibited accelerated activation kinetics (Fig. 6 B and inset), suggesting that retigabine remains associated with channels during repolarization-induced closure, leading to accelerated activation during subsequent depolarizations.
The ICA73 has much more prominent effects on channel deactivation, requiring up to 20-s repolarizations for complete channel closure at −120 mV (Fig. 7 C). Using longer interpulse intervals to achieve intermediate levels of channel closure, we observed that activation kinetics were unchanged relative to the control condition. We interpret this result to mean that channel closure requires ICA73 unbinding. Thus, channels that close during the interpulse interval are no longer bound to ICA73 and therefore exhibit activation kinetics identical to control conditions (Fig. 7 D).
A voltage sensor mutation accelerates ICA73 unbinding
We recently described the KCNQ2[A181P] mutation that attenuates ICA73-mediated gating effects but preserves current potentiation (Wang et al., 2017). Specifically, KCNQ2[A181P] mutant channels exhibit modest deceleration of channel deactivation in the presence of ICA73, leading to a weaker apparent shift of the conductance–voltage relationship relative to WT KCNQ2. The specific mechanism underlying this effect was not clear, and we speculated that this weaker gating effect might reflect a loss of the strict state dependence of ICA73 (allowing KCNQ2[A181P] channels to close even when bound to ICA73) or, alternatively, a faster unbinding rate reflecting weakened affinity.
We tested these possibilities using rapid solution application, as described in Figs. 2 and 5. This experiment demonstrates that ICA73 association with KCNQ2[A181P] becomes very slow at negative voltages, similar to what was observed for WT KCNQ2 (Figs. 2 and 7). There is a pronounced voltage dependence of ICA73 interaction with KCNQ2[A181P] channels, which tracks the voltage dependence of A181P conductance. The onset of ICA73 effects are extremely slow or absent at voltages more negative than −80 mV (Fig. 8, B and C).
We also compared the association and dissociation rates of ICA73 in WT KCNQ2 and KCNQ2[A181P] channels using rapid solution exchange (Figs. 9 and 10). Drug binding at 0 mV had similar time constants of ∼500 ms between WT KCNQ2 and KCNQ2[A181P] channels, suggesting that ICA73 binding is not strongly affected by the A181P mutation. This experiment differs slightly from Fig. 7 in that we focused on applying the drug at voltages where channels were fully activated and the ICA73 binding site was maximally accessible. Thus, channel transitions between resting and activated states would not influence the observed rate of interaction.
When ICA73 is rapidly washed off, there is very slow relaxation of currents in WT KCNQ2 channels, ranging from a time constant of ∼6 s (at 0 mV) to ∼2 s (at −150 mV; Fig. 10). This likely reflects very slow dissociation of ICA73 from the channels. Across all voltages tested, ICA73 dissociation from A181P channels was considerably faster (∼10-fold) than dissociation from WT KCNQ2, suggesting that the primary mechanism underlying the weakened ICA73 gating effects in KCNQ2[A181P] channels is accelerated unbinding reflecting weakened affinity, allowing for more rapid channel closure at negative voltages. Superimposed on these data in Fig. 10 C is the voltage dependence of channel closure for WT KCNQ2 and KCNQ2[A181P] channels. In the absence of ICA73, KCNQ2 and A181P channels deactivate with comparable kinetics, so intrinsic differences in channel gating do not account for the dramatic difference in ICA73 unbinding.
Retigabine-sensitive KCNQ channel isoforms (KCNQ2-5) have been targeted in the development of voltage-gated potassium channel openers (Barrese et al., 2018; Miceli et al., 2018). Large compound libraries have been screened in recombinant systems and animal models, and several reports have documented openers with enhanced subtype specificity and increased potency toward certain KCNQ channel types (Padilla et al., 2009; Blom et al., 2010; Brueggemann et al., 2014). Some openers, such as ICA73, cause extremely large gating effects relative to retigabine on certain KCNQ subtypes, such as KCNQ2. Although many KCNQ channel openers act on the canonical retigabine site formed by a conserved Trp residue in the pore domain (Bentzen et al., 2006; Lange et al., 2009), it is now recognized that certain KCNQ openers are resistant to mutation of the retigabine site and instead act at an alternative voltage sensor site (Padilla et al., 2009; Gao et al., 2010; Peretz et al., 2010; Li et al., 2013; Wang et al., 2017). Consistent with this finding, point mutations in the voltage sensor (KCNQ2 A181 and F168) alter sensitivity to VSD-targeted drugs like ICA73 but not retigabine (Wang et al., 2017).
These structure–function approaches provide strong evidence for an alternative site for KCNQ openers, formed by the voltage sensor, in addition to the pore-delimited retigabine site. In this study, we used rapid solution switching to demonstrate fundamentally different mechanisms of action for pore- (retigabine) versus voltage sensor–targeted (ICA73) KCNQ openers. Most convincingly, the rate of ICA73 association with KCNQ2 closely tracks the voltage dependence of channel activation, whereas the rate of retigabine access is affected by membrane voltage much less prominently (Figs. 2 and 5). The ICA73 association with resting states of the channel is extremely slow (possibly completely occluded), as incubation of KCNQ2 in ICA73 has no effect on channel opening until a depolarization is delivered, channels open, and the binding site becomes accessible (Fig. 1). In contrast, retigabine association with KCNQ2 does not follow the same strict dependence on channel activation, and drug effects are apparent during retigabine incubation at negative voltages where most channels are closed. Hints of this dependence on channel activation have appeared in pharmacological investigations of spinal reflexes, in which pore-targeted activators (retigabine, ML-213) rapidly suppress responses evoked by dorsal root stimulation, whereas ICA73 has a slower onset (many action potentials fire before the drug effect becomes apparent; Vicente-Baz et al., 2016).
Synthesizing data from mutagenesis and rapid solution perfusion, a reasonable explanation for our findings is that ICA73 (and likely related compounds like ICA-27243) binds nearly exclusively to activated states of the voltage-sensing domain. Thus, when channels are at rest, very few (if any) bind to ICA73, and activation kinetics are comparable to control conditions. After a voltage sensor reaches an active state, ICA73 can bind and dramatically decelerate voltage sensor deactivation, causing homomeric KCNQ2 channels to be trapped in an activated conformation for extended durations (Fig. 11 A). This pronounced state dependence differs significantly from retigabine (Fig. 11 B). The distinct mechanisms of action of these drugs are consistent with our recent findings that the stoichiometric requirement for channel activation is different for pore- versus VSD-targeted openers. The KCNQ3 activation by retigabine is nearly maximal in tetramers with a single retigabine-sensitive subunit. In contrast, ICA73 activation of KCNQ2 requires four drug-sensitive subunits for maximal drug effect, leading us to suggest that this multisubunit dependence may be caused by unique features of VSD–pore coupling in KCNQ channels (Wang et al., 2018; Yau et al., 2018). That is, activation of intermediate numbers of voltage sensors may underlie channel states with intermediate open probability or conductance.
Although the existence of an alternative VSD-delimited binding site is supported by several prior findings (Padilla et al., 2009; Gao et al., 2010; Peretz et al., 2010; Wang et al., 2017), details of the structural determinants of this binding site have been more difficult to describe with certainty. Our sequence comparison study between KCNQ2 and KCNQ3 led to the identification of KCNQ2 residues A181 and F168 as important determinants of sensitivity but does not demonstrate whether they directly contribute to binding (Wang et al., 2017). Based on the recent KCNQ1 cryo-EM structure, the predicted α-carbon distance between these two amino acid positions is ∼18 Å, while the end-to-end length of ICA73 is ∼12 Å, so it is unlikely that both amino acids contribute to a binding site (Sun and MacKinnon, 2017). More importantly, we have also demonstrated that ICA73 sensitivity persists in many A181 mutants (A181L and A181G; Wang et al., 2017). Only the more disruptive A181P substitution was found to diminish ICA73 effects. Other amino acids in the vicinity of A181 (E130, Y127, and R207) have also been suggested to play a role in a class of diclofenac derivatives that target the voltage sensor, and so a possible explanation for our findings is that the A181P substitution distorts the conformation of this region and weakens the affinity for ICA73 (leading to a faster dissociation rate as reported here), rather than making essential direct contacts with the drug. Although the effects of mutating F168 are more prominent, leading to complete loss of ICA73 sensitivity, it is more distant from this cluster of residues and has also been suggested to influence stability of the activated voltage sensor (Miceli et al., 2013). Thus, mutation of F168 may have indirect effects on voltage sensor activation that prevent ICA73 binding or effects. Further functional and structural studies of the mechanisms of voltage sensor–targeted KCNQ openers will be required to describe the binding site of these compounds in more detail.
In summary, our study illustrates critical mechanistic differences between pore- and voltage sensor–targeted activators. These findings compliment previous structure–function experiments that delineate different structural requirements for sensitivity to these different drugs and also reveal important details related to drug binding to specific channel states.
This study was funded by Canadian Institutes of Health Research operating grant MOP 142482. C.K. Wang was supported by a Canadian Institutes of Health Research CGS-M graduate award. H.T. Kurata was supported by a Canadian Institutes of Health Research New Investigator Award and the Alberta Diabetes Institute.
The authors declare no competing financial interests.
Author contributions: C.K. Wang, S.M. Lamothe, and H.T. Kurata designed the experiments. C.K. Wang, S.M. Lamothe, A.W. Wang, and R.Y. Yang performed experiments. C.K. Wang, S.M. Lamothe, and H.T. Kurata analyzed data. C.K. Wang and H.T. Kurata wrote the manuscript. All authors provided edits and approved the final version of the manuscript.
Kenton J. Swartz served as editor.